Leo Pharma’s Enstiloom acquires approval as psoriasis treatment in Korea

On the 16^th, Leo Pharma Korea(President Kasper Kunzel) announced Enstiloom(generic name: calcipotriol/betamethasone dipropionate 50 micrograms/g / 0.643 mg/g), an external aerosol-form-type psoriasis treatment was recently approved to use in Korea.

Psoriasis vulgaris is the most common clinical type of psoriasis, which is contracted on about 1% of people in Korea and more than 4 million people...